Quantidoc
Immune barrier health monitoring for fish farms and hatcheries using its VERIBARR™ analyses of gills, skin and gut
Highlights
- New on EvolcAdded 2026-10-28
About Quantidoc
QUANTIDOC is a Norwegian biotech company that develops VERIBARR™, a technology that measures the area and density of frontline mucus cells in fish gills, gut and skin to assess barrier health. Three VERIBARR™ solutions are offered: a single-point start analysis, effect analysis and mapping, and continuous analysis and mapping.
Its customers are fish farmers, operators of recirculating aquaculture systems, smolt producers and feed companies. The company has partnerships with Stim Chile in South America, the Atlantic Veterinary College in Canada, Ictiovet in Spain and the Fisheries Research Institute of Malaysia.
QUANTIDOC was founded in 2013 and is based in Bergen, Norway. The company states that VERIBARR™ is applied across 13 fish species worldwide.
Product: VERIBARR™ barrier-health analyses for fish, offered as start analysis, effect analysis and mapping, and continuous analysis and mapping.
Jobs at Quantidoc
Leadership
- Jacob Grieg Eide · CEOSource: company website
- Karin Pittman · CEOSource: company website
More biotech & pharma companies
Regenics
Develops marine-derived wound care products for treating burns and chronic woundsNew on EvolcThor Medical
Produces thorium-derived alpha-particle emitters for makers of radioligand cancer therapies and research usersNew on EvolcTribune Therapeutics
Preclinical biopharma developing anti-fibrotic medicines that target CCN signaling, for patients with fibrotic diseaseNew on EvolcVitas
Contract analytical lab in Oslo running DBS biomarker analysis and GMP pharma quality testing for drug, food and research clientsNew on EvolcZelluna
Clinical-stage biotech developing TCR-guided NK cell therapies for solid cancers, led by ZI-MA4-1 in a Phase 1 trialNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Squarespace